Video

20 June 2016

BIO-Europe Spring® 2016: RMI says it has USD 200 million already under management

EBD Group

Maxim Gorbachev, a partner and portfolio manager at RusnanoMedInvest (RMI) speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio about Russia’s and Eastern Europe’s largest venture capital company, specializing in innovative developments in the field of pharmaceuticals and biotechnology. 

22 June 2015

Leonid Melamed: uncertainty period is the best time to make important tactical and strategical decisions

June 25, 2015, Vedomosti newspaper office will host a FocusForum Conference in Moscow with a leading participation of Leonid Melamed, the Chairman of Team Drive, member of the Board of Directors of NovaMedica, RMI Partners and Doctor Ryadom. The conference’s goal is to gather experts and share ideas and valuable experience in the time of business challenges. In his video interview to Vedomosti, Leonid explained his vision of the company management tasks in the period of uncertainty. 

23 May 2014

SPIEF2014. Leonid Melamed: Apparently, the one, who shall benefit from the development of public-private partnerships, is the patient

In general terms, engagement of private companies in the healthcare system on a competitive basis shall result in the price optimization and improvement of the quality of medical services provided and pharmaceuticals delivered to patients, Leonid Melamed, Chairman of the Board, Team Drive; Member of the Board of Directors, RusnanoMedInvest and NovaMedica said on Friday at St. Petersburg SPIEF2014.

12 February 2013

Brian Dovey, Domain Associates LLC - speaking about VC/Rusnanotech 2011

Brian Dovey, Partner, Domain Associates LLC (one of the first venture capital firms to exclusively invest in the life sciences sector) -  speaking about VC (Rusnanotech 2011)

21 June 2012

St. Petersburg International Economic Forum

Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets